The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains an incurable disease with unavoidable relapses, and the outcome after pomalidomide is still dismal. However, some patients demonstrate prolonged survival even beyond pomalidomide therapy.
We sought to analyze the treatment of RRMM patients following Pom-Dex therapy and the response and survival after this next treatment line.
We studied 134 patients treated with Pom-Dex until progression across two IFM studies. Seventy percent of these patients received further therapy after Pom-Dex. Among the treated patients, one third responded and one third maintained stable disease. The median OS for treated patients was 12 months (6.5;17), with 22 and 12.5% of patients surviving beyond 2 and 3 years, respectively. The factors associated with a better outcome were exposure to a triplet-based regimen containing a novel agent, response to therapy, absence of adverse cytogenetic, and a longer time from diagnosis to post pomalidomide therapy.
This study suggests that patients relapsing after Pom-Dex therapy can still benefit from a further line of treatment. A subset of these treated patients even displayed a prolonged OS, while the prognosis remained very poor without treatment. An active approach could therefore be recommended even in this adverse situation, however guided by the patients’ prognosis factors.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79(7):867–874. https://doi.org/10.4065/79.7.867
European Medicines Agency. Imnovid (pomalidomide). Summary of product characteristics. Available from http://www.ema.europa.eu. Accessed Aug 2013
U.S. Food and Drug Administration. POMALYST (pomalidomide). Approved Drugs. Available from http://www.fda.gov/Drugs. Accessed Dec 2013
Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Brechignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T, on behalf of Intergroupe Francophone du Myelome (2013) Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 121(11):1968–1975. https://doi.org/10.1182/blood-2012-09-452375
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123(12):1826–1832. https://doi.org/10.1182/blood-2013-11-538835
San Miguel J et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055–1066. https://doi.org/10.1016/S1470-2045(13)70380-2
Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3–9. https://doi.org/10.1038/leu.2008.291
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, on behalf of the International Myeloma Workshop Consensus Panel 1 (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691–4695. https://doi.org/10.1182/blood-2010-10-299487
Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T, for the Intergroupe Francophone du Myelome (IFM) (2015) Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood 125(9):1411–1417. https://doi.org/10.1182/blood-2014-11-612069
Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 3(9):e143. https://doi.org/10.1038/bcj.2013.38
Richardson PG, Mark TM, Lacy MQ (2013) Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol 88(Suppl 1):S36–S44. https://doi.org/10.1016/j.critrevonc.2013.02.001
Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JFS (2014) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573–1585. https://doi.org/10.1038/leu.2014.60
Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S (2016) Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127(21):2561–2568. https://doi.org/10.1182/blood-2015-11-682518
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, ASPIRE Investigators (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152. https://doi.org/10.1056/NEJMoa1411321
The authors wish to thank the patients and their family. The authors thank Celgene for providing investigational products. They thank Dr. Bernadette Hennache, Dr. Suzanna Schraen, Mr. Jean Luc Faucompret, and Mr. Jaime Gutierrez for the central laboratory analysis in CHRU of Lille, France; Christine Cotton and Florence Carrère from Statitec (Toulouse, France) for data management and statistical analysis; and Bella Ohyba, Chanaz Louni, Mehdi Hamza, and Malek Dib, for the Direction de la Recherche Clinique of CHRU of Lille, France.
The patients, their family, the Department of Hematology of Poitiers, CHU, France, and her colleagues wish to thank Dr. Laurence Lacotte-Thierry, a wife and beloved mother of three, hematologist, and myeloma physician, that died on 2016, from a long unended fight against cancer.
The authors thank Celgene for financial support for IFM 2009-02 and IFM 2010-02
The study was approved by the CHRU of Lille review board, and it was conducted according to the Declaration of Helsinki.
Conflict of interest
The authors declare that they have no conflict of interest.
GF, LK, MM, and DC are the co-first authors
About this article
Cite this article
Fouquet, G., Karlin, L., Macro, M. et al. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. Ann Hematol 97, 831–837 (2018). https://doi.org/10.1007/s00277-018-3236-6
- Multiple myeloma